FORMATO EUROPEO PER IL CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	**FURLAN ROBERTO**
Indirizzo	**VIA CAMPO DEI FIORI, 32 20026 NOVATE MILANESE (MI)**
Telefono	**02-26434867**
Fax	**02-26434855**
E-mail	**furlan.roberto@hsr.it**
Codice Fiscale	**FRLRRT64D05Z112S**
Nazionalità	italiana
Data di nascita	5 APRILE 1964

ESPERIENZA LAVORATIVA

• Date (da – a)	2023-present
• Nome e indirizzo del datore di lavoro	Vita e Salute University, Milano, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Associate Professor in General Pathology
• Date (da – a)	2022-present
• Nome e indirizzo del datore di lavoro	Institute of Experimental Neurology, Ospedale San Raffaele, Milano, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Director
• Principali mansioni e responsabilità	
• Date (da – a)	2017-2021
• Nome e indirizzo del datore di lavoro	Institute of Experimental Neurology, Ospedale San Raffaele, Milano, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Deputy Director
• Principali mansioni e responsabilità	
• Date (da – a)	2015-present
• Nome e indirizzo del datore di lavoro	Clinical Neuroimmunology Unit, Dept. of Neuroscience, Ospedale San Raffaele, Milano, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Head of Unit
• Principali mansioni e responsabilità	
• Date (da – a)	2004-2022
• Nome e indirizzo del datore di lavoro	Vita e Salute University, Milano, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Non-tenured professor
• Principali mansioni e responsabilità	
• Date (da – a)	2002-2015,

Per ulteriori informazioni:
www.cedefop.eu.int/transparency
www.europa.eu.int/comm/education/index_it.html
www.eurescv-search.com

• Nome e indirizzo del datore di lavoro	Neuroimmunology Unit, Dept. of Neuroscience, DIBIT-San Raffaele Scientific Institute, Milano, Italy.
• Tipo di azienda o settore	
• Tipo di impiego	Group leader
• Date (da – a)	1999-2001
• Nome e indirizzo del datore di lavoro	University of Milan, Milan, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Non-tenured Research Assistant
• Date (da – a)	1996-99
• Nome e indirizzo del datore di lavoro	Neuroimmunology Unit, Dept. of Neuroscience, DIBIT-San Raffaele Scientific Institute,Milano,Italy.
• Tipo di azienda o settore	
• Tipo di impiego	Post-doctoral fellow
• Date (da – a)	1994-95
• Nome e indirizzo del datore di lavoro	Dept. of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, U.S.A.
• Tipo di azienda o settore	
• Tipo di impiego	Post-doctoral fellow
• Date (da – a)	1993
• Nome e indirizzo del datore di lavoro	Clinical Laboratories, Sao Rafael Hospital, Salvador-Bahia, Brazil.
• Tipo di azienda o settore	
• Tipo di impiego	Visiting Scientist
• Date (da – a)	1992
• Nome e indirizzo del datore di lavoro	Department of Neurology, University of Chicago, U.S.A.
• Tipo di azienda o settore	
• Tipo di impiego	Visiting Scientist
• Date (da – a)	1991-94
• Nome e indirizzo del datore di lavoro	Neuroimmunology Unit - DIBIT, San Raffaele Scientific Institute, Milan, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Post-doctoral fellow
• Date (da – a)	1990-91
• Nome e indirizzo del datore di lavoro	Laboratory of Neurophysiology and Cellular Neurobiology, Department of Neurology, University of Milan, San Raffaele Scientific Institute, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Internship
• Date (da – a)	1988
• Nome e indirizzo del datore di lavoro	Institute of Pharmacology, University of Milano, San Raffaele Scientific Institute, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Internship
• Date (da – a)	1984-85
• Nome e indirizzo del datore di lavoro	"M. Negri" Institute for Pharmacology Research, Milano, Italy
• Tipo di azienda o settore	
• Tipo di impiego	Research Fellow

ISTRUZIONE E FORMAZIONE

• Date (da – a)	2002-2007

• Nome e tipo di istituto di istruzione o formazione	Via e Salute San Raffaele University, Milano, Italy
• Principali materie / abilità professionali oggetto dello studio	
• Qualifica conseguita	Residency in Neurology
• Livello nella classificazione nazionale (se pertinente)	
• Date (da – a)	1997-2001
• Nome e tipo di istituto di istruzione o formazione	Open University, London, UK
• Principali materie / abilità professionali oggetto dello studio	
• Qualifica conseguita	PhD
• Livello nella classificazione nazionale (se pertinente)	
• Date (da – a)	1984-1991
• Nome e tipo di istituto di istruzione o formazione	University of Milano, Italy
• Principali materie / abilità professionali oggetto dello studio	
• Qualifica conseguita	Medical Degree (110/110 and honours)
• Livello nella classificazione nazionale (se pertinente)	
• Date (da – a)	1983
• Nome e tipo di istituto di istruzione o formazione	High School "S.Allende", Milano, Italy
• Principali materie / abilità professionali oggetto dello studio	
• Qualifica conseguita	Matriculation, (58/60)
• Livello nella classificazione nazionale (se pertinente)	

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA	**ITALIAN**
ALTRE LINGUE	
	GERMAN
• Capacità di lettura	EXCELLENT
• Capacità di scrittura	EXCELLENT
• Capacità di espressione orale	EXCELLENT
	ENGLISH
• Capacità di lettura	EXCELLENT
• Capacità di scrittura	EXCELLENT
• Capacità di espressione orale	EXCELLENT
CAPACITÀ E COMPETENZE RELAZIONALI *Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti*	[Descrivere tali competenze e indicare dove sono state acquisite.]

in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

CAPACITÀ E COMPETENZE ORGANIZZATIVE
Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

CAPACITÀ E COMPETENZE TECNICHE
Con computer, attrezzature specifiche, macchinari, ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

CAPACITÀ E COMPETENZE ARTISTICHE
Musica, scrittura, disegno ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

ALTRE CAPACITÀ E COMPETENZE
Competenze non precedentemente indicate.

1992 Fellowship, "Associazione Italiana Sclerosi Multipla", Genova, Italy
1994 Fellowship, "Istituto Superiore di Sanità", Roma, Italy
1995 De Visart" Award for Neurological Research, University of Milano, Italy
1999 Teva and Marion Hoechst Award on MultipleSclerosis, European Charcot Found.
2002 European Neurological Society award for the scientific paper " Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57BL/6 mice.", Berlin 22-26 June.
2009 Rita Levi Montalcini Award, AISM, Roma, Italy
2009 Board member of the Italian Nueroimunology Association - AINI
2010 Scientific Board member of the Italian Multiple Sclerosis Association – AISM
2010-18 Secretary-Treasurer of the International Neuroimmunology Society – ISNI
2011 SIICA Best Abstract Awards for "Microvesicles in the cerebrospinal fluid reflect microglia/macrophage activation in rodent and human neuro-inflammation". Riccione 28 sept.-1 oct.
2021-23 Vice President (President elect) of the International Society of Neuroimmunology– ISNI

Reviewer for the following journals: Brain, Neurology, European Journal of Neurology, Human Gene Therapy, Journal of Immunology, European Journal of Immunology, Journal of Neuroimmunology, Multiple Sclerosis, Neuroscience Letters, Journal of Gene Medicine, Molecular and Cellular Neurological Sciences.
Reviewer for the following granting agencies: Fondazione Italiana Sclerosi Multipla – FISM, Association pour la Recherche de la Sclerose en Plaque – Arsep. NHS Foundation Trust.

PATENTE O PATENTI

ULTERIORI INFORMAZIONI

Abilitation as Full Professor in General Pathology and Applied Biology, Ministry of University 2014.

ALLEGATI

[Se del caso, enumerare gli allegati al CV.]

1. Publications

>250 pubblicazioni in giornali internazionali peer reviewed. Orcid 0000-0001-7376-9425; Scopus Author ID: 7005770529; ResearcherID: J-9177-2016

H-index attuale: Google Scholar = 80, last 5 years = 51. Scopus = 67.

1. Grimaldi LME, Luzi L, Martino GV, Furlan R, Nemni R, Canal N, Pozza G, Antonelli G. Bilateral VIII cranial nerve neuropathy as initial manifestation of human immunodeficiency virus infection. J. Neurol. 1993; 240:363-366 (I.F. 2.3)

2. Martino GV, Grimaldi LME, Servalli C, Filippi M, Furlan R, Martinelli V, Comi G. Absence of immunoglobulin restriction in tears from multiple sclerosis patients. J. Neuroimmunol. 1993; 44:149-156 (I.F. 3.3)

3. Grimaldi LME, Martino G, Braghi S, Quattrini A, Furlan R, Bosi E, Comi G. Heterogeneity of autoantibodies in stiff-man syndrome. Ann. Neurol. 1993; 34:57-64 (I.F. 9.5)

4. Furlan R., Salazar-Grueso E.F., Martino G., Lillo F., Kotulski M., Brambilla E., Castellano M., Terreni M.R., Roos R.P., Grimaldi L.M.E. HTLV-I hu-SCID mouse in the study of HTLV-I neurotropism. Ann. N.Y. Aca. Sci. 1994; 724:422-5 (I.F. 1.0)

5. Martino G., Furlan R., Brambilla E., Castellano M.,Terreni M.R., Comi G.,Grimaldi L.M.E Absence of central nervous system pathology in severe combined immunodeficiency mice intraperitoneally injected with blood lymphocytes from multiple sclerosis patients. J. Neuroimmunol. 1994; 55:213-7 (I.F. 3.3)

6. Furlan R, Martino G, Salazar-Grueso EF, Brambilla E, Castellano M, Cao J, Lillo F, Terreni Mr, Bacellar H, Roos RP, Grimaldi LME. A model of HTLV-I infection in the SCID mouse. J. Med. Virol. 1996; 49:77-82 (I.F. 2.6)

7. Grimaldi LME, Murthy KK, Martino G, Furlan R, Franciotta D, Eichberg JW. An Immunovirological study of central nervous system involvement during HIV-1 infection of chimpanzees. J. AIDS Hum. Retr.1996; 13:12-17 (I.F. 2.3)

8. Martino G, Furlan R, Galbiati F, Poliani PL, Bergami A, Grimaldi LME, Adorini L, Comi G. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Multiple Sclerosis. 1998 4:222-227 (I.F. 2.1).

9. Furlan R, Poliani Pl, Galbiati F, Bergami A, Grimaldi LME, Comi G, Adorini L, Martino G. Central nervous system delivery of Interleukin-4 by a non replicative Herpes Simplex Type I viral vector ameliorates autoimmune demyelination. Hum. Gene Ther. 1998 9:2605-2617 (I.F. 5.6).

10. Schaer Barbosa H, Lisboa Bittencourt A, Barreto De Araujo I, Sampaio Pereira C, Furlan R, Pedrosa C, Lessa G, Galvao Castro B. Adult T-cell leukemia/lymphoma in northeastern Brazil: a clinical, histopathological and molecular study. J. AIDS Hum. Retr. 1999 21:65-71.

11. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 1999 163:2403-2409 (I.F. 7.2)

12. Furlan R, Filippi M, Bergami A, Rocca MA, Martinelli V, Poliani PL, Desina G, Comi G, Martino G. Peripheral levels of caspase-1 mRNA correlate with disease activity in multiple sclerosis patients: a preliminary study. J. Neurol. Neuros. Neuropsych. 1999;67:785-788 (I.F. 2.9).

13. Sipe JC, Filippi M, Martino G, Furlan R, Rocca MA, Rovaris M, Bergami A, Scotti G, Comi G, Zyroff J. Intracellular magnetic labelling of human lymphocytes with Endorem and Feridex: possible use for central nervous system (CNS) trafficking studies in multiple sclerosis. Magnetic Resonance Imaging. 1999;17:1521-1523 (I.F. 1.2).

14. Del Maschio A, De Luigi A, Martin-Padura I, Brockhaus M, Bartfai T, Fruscella P, Adorini L, Martino G, Furlan R, De Simoni MG, Dejana E. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to Junctional Adhesion Molecule (JAM). J. Ex. Med. 1999;190:1351-1356 (I.F. 15.6)

15. Martino G, Poliani PL, Furlan R, Marconi P, Glorioso JC, Adorini L, Comi G. Cytokine Therapy in Immune-mediated Demyelinating Diseases of the Central Nervous System: a Novel Gene Therapy Approach. J. Neuroimmunol. 2000;107:184-190 (I.F. 3.3).

16. Gironi M, Martinelli V, Brambilla E, Furlan R, Panerai AE, Comi G, Sacerdote P. beta-Endorphin concentration in peripheral blood mononuclear cells of patients with multiple sclerosis - effects of treatment with interferon beta. Arch. Neurol. 2000 57:1178-1181 (I.F. 3.4).

17. Martino G, Poliani PL, Marconi P, Furlan R. Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors. Gene Ther. 2000;7:1087-1093 (I.F. 5.4).

18. Martino G, Furlan R, Poliani PL. The pathogenic role of inflammation in multiple sclerosis. Rivista de Neurologia. 2000;30:1213-1217 (I.F. 2.3).

19. Martino G, Furlan R. Terapia genica immunomodulante nelle malattie demielinizzanti. Neurol. Sci. 2000;21:S675-S680

20. Martino G, Furlan R, Brambilla E., Bergami A., Ruffini F, Gironi M, Poliani Pl, Grimaldi Lme, Comi G. Cytokines and Immunity in Multiple Sclerosis: the Dual Signal Hypothesis. J Neuroimmunol. 2000;109:3-9 (I.F. 3.3).

21. Gironi M, Bergami A, Brambilla E, Ruffini F, Furlan R, Comi G, Martino G. Immunological markers in multiple sclerosis. Neurol. Sci. 2000;21(suppl. 2):S871-S875.

22. Furlan R, Brambilla E, Lang R, Martinelli V, Bergami A, Desina G, Grimaldi LME, Comi G, Panina P, And Martino G. Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-g and interleukin-4. J. Neuroimmunol. 2000;111:86-92 (I.F. 3.3).

23. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L, Glorioso JC, Comi G, Martino G. Interleukin-4 gene delivery in the central nervous system at the time of disease onset inhibits progression of autoimmune demyelination. Gen. Ther. 2001;8:13-19 (I.F. 5,4).

24. Franciotta DM, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J. Neuroimmunol. 2001;115(1-2):192-8 (I.F. 3.3).

25. Poliani PL, Brok H, Furlan R, Ruffini F, Bergami A, Desina G, Marconi PC, Rovaris M, Glorioso JC, Penna G, Adorini L, Comi G, t'Hart B, Martino G. Delivery of a non-replicative herpes simplex type-1 vector engineered with the IL-4 gene to the central nervous system protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum. Gene Ther. 2001;12:905-920 (I.F. 5.6).

26. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, Martino G. Intrathecal delivery of IFNγ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of CNS-infiltrating lymphocytes. J. Immunol. 2001; 167:1821-1829 (I.F. 7.2)

27. Ruffini F, Furlan R, Poliani PL, Brambilla E, Marconi PC, Bergami A, Desina G, Glorioso JC, Comi G, Martino G. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gen Ther. 2001;8:1207-1213 (I.F. 5.4)

28. Martino G, Furlan R, Comi G, Adorini L. The ependymal route to access the central nervous system: an emerging immuno-gene therapy approach to multiple sclerosis. Trends Immunol. 2001; 22:483-490 (I.F. 15.4)

29. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Gironi M, Bergami A, Angelini G, Benedetti Fd, Pignatti P, Moscato G, Cosi V. Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. Eur Cytokine Netw. 2002; 13:99-103. (I.F. 1.7)

30. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57BL/6 mice. Brain. 2003; 126:285-291. (I.F. 7.4)

31. Furlan R, Pluchino S, Marconi PC, Martino G. Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. Methods Mol Biol. 2003; 215:279-289.

32. Gironi M, Furlan R, Rovaris M, Comi G, Filippi M, Panerai AE, Sacerdote P. Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2003 74:495-497. (I.F. 2.9)

33. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Bergami A, Furlan R, Delcarro U, Amadio S, Comi G, Vescovi Al, Martino G. Intravenous and intracerebroventricular injection of adult neurospheres induces clinical recovery in a chronic model of multiple sclerosis. Nature 2003; 422:688-694 (I.F. 27.955).

34. Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona P, Casorati G, Martino G. Activation of invariant NKT cells by α-GalCer administration protects mice from MOG35-55-induced EAE: a critical role for administration route and IFNγ. Eur J Immunol. 2003; 33:1830-1838. (I.F. 4.536)

35. Furlan R. Pluchino S, Martino G. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol. 2003; 16:385-392. (I.F. 4.035)

36. Furlan R. Pluchino S, Martino G. Gene therapy-mediated modulation of immune processes in the central nervous system. Curr Pharm Des. 2003; 9:2002-2008. (I.F. 4,6)

37. Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R, Lavolpe V, Vincent A, Comi G, Trojano M, Montalban X, Martino G. Serial immunoprecipitation assays for interferon (IFN)β antibodies in MS patients. Eur. Cyt. Net. 2003 14:154-7. (I.F. 1.7)

38. Morini M, Roccatagliata L, Dell'eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese M, Noonan D, Mancardi G, Albini A, Uccelli A. Alpha lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004 148:146-153. (I.F. 3.6)

39. Furlan R, Villa P, Senaldi G, Martino G. Animal models of TNF-α-mediated diseases of the central nervous system. Methods Mol. Med. 2004 98:171-90.

40. Furlan R, Salani G, Bergami A, Martino G. Detection of TNF and TNF receptor mRNA in cells and tissues. Methods Mol. Med. 2004 98:59-72.

41. Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, Gasparini L, Butti E, Comi G, Ongini E, Martino G. The nitric oxide (NO)-releasing derivative of flurbiprofen, HCT 1026, inhibits experimental autoimmune encephalomyelitis in C57BL/6 mice. A possible role for regulatory T cells. J. Neuroimmunol. 2004 150:10-19. (I.F. 3.6)

42. Pluchino S, Furlan R And Martino G. Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies. Curr Opin Neurol. 2004 17:247–255 (I.F. 4.035)

43. Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology. 2004 62:2092-2094 (I.F. 5.340)

44. Furlan R. MBP-specific experimental autoimmune encephalomyelitis in C57BL/6 mice. J Immunol. 2004 173:5 (Letter to the Editor). (I.F. 6.486)

45. Furlan R, Butti E, Pluchino S, Martino G. Gene therapy for autoimmune diseases. Curr Opin Mol Ther. 2004 6:525-536

46. Pedotti R, Aloisi F, Martino G, Furlan R. Conference report. Highlights from the Seventh International Congress of the International Society of Neuroimmunology. J Neuroimmunol. 2005 162:5-11 (I.F. 2.704).

47. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, Martinello M, Cattalini A, Bergami A, Furlan R, Comi G, Constantin G, Martino G. Neurosphere-derived multipotent precursors promote long-lasting neuroprotection by an immunomodulatory mechanism. Nature 2005 436:266-271 (I.F. 32.182).

48. Furlan R, Rovaris M, Khademi M, Martinelli Boneschi F, Bergami A, Gironi M, Deleidi M, Agosta F, Scarpini E, Zaffaroni M, Uccelli A, Franciotta D, Kurne A, Comi G, Olsson T, Filippi M, Martino G. Immunological patterns identifying disease course and disease evolution in multiple sclerosis patients. J Neurimmunol. 2005 165:192-200. (I.F. 2.704).

49. Pluchino S, Bacigaluppi M, Bucello S, Butti E, Deleidi M, Zanotti L, Martino G, Furlan R. Gene and stem cell therapy for autoimmune demyelination. Ernst Schering Res Found Workshop. 2005; 53:133-46.

50. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive MS: current knowledge and future challenges. Lancet Neurol. 2006 5:343-354. (I.F. 12.167)

51. Furlan R, Bergami A, Brambilla E, Butti E, De Simoni Mg, Campagnoli M, Marconi PC, Comi G, Martino G. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG35-55 induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2007 14:93-98. (I.F. 4.836)

52. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007 30:2543-2553. (I.F. 7.617)

53. Muzio L, Martino G, Furlan R. Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol. 2007 191: 39-44. (I.F. 2.880)

54. Butti E, Bergami A, Recchia A, Brambilla E, Franciotta D, Cattalini A, Stornaiuolo A, Comi G, Mavilio F, Martino G, Furlan R. Absence of an intrathecal immune reaction to a HD adenoviral vector delivered into the cerebrospinal fluid of non-human primates. Gene Ther. 2008 15: 233-238. (I.F. 4.782)

55. Butti E, Bergami A, Recchia A, Brambilla E, Del Carro U, Amadio S, Cattalini A, Stornaiuolo A, Comi G, Pluchino S, Mavilio F, Martino G, Furlan R. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther. 2008 15: 504-515. (I.F. 4.782)

56. Lampasona V, Belloni C, Piquer S, Furlan R, Bonifacio E. Radiobinding assay for detecting autoantibodies to single epitopes. J Immunol. Meth. 2008 336:127-34. (I.F. 2.402)

57. Centonze D, Furlan R, Gasperini C, Salvetti M, Battistini L. Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Mult. Scler. 2008 14:1137-8. (I.F. 2.773)

58. Furlan R. Definition of non responders: biological markers. Neurol. Sci. 2008 29:S47-51. (I.F. 0.894)

59. Meloni F, Accapezzato D, Agresti C, Aloisi F, Ristori G, Salvetti M, Furlan R, Martino G, Barnaba V, Paroli M. Dendritic cells loaded with apoptotic oligodendrocytes as a source of myelin T cell epitopes in multiple sclerosis. Clin. Immunol. 2008 129:286-94. (I.F. 3.551)

60. Bianco F, Perrotta C, Novellino L, Francolini M, Saglietti L, Menna E, Furlan R, Schuchman EH, Clementi E , Matteoli M, Verderio C. Acid sphyngomyelinase activity triggers microparticle release from glial cells. EMBO J. 2009 28:1043-54. (I.F. 8.662)

61. Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, Saglietti L, Schuchman EH, Furlan R, Clementi E, Matteoli M, Verderio C. Acid sphingomyelinase activity triggers microparticle release from glial cells (The EMBO Journal (2009) 28 (1043-1054) Embo J. 2009; 28: 1374 – Erratum (I.F. 8.662)

62. Brini E, Ruffini F, Bergami A, Brambilla E, Dati G, Greco B, Cirillo R, Proudfoot AEI, Comi G, Furlan R, Zaratin P, Martino G. Administration of a monomeric CCL2 variant to EAE mice prevents inflammatory cell recruitment and protects from demyelination and axonal loss. J Neuroimmunol. 2009 290:33-39. (I.F. 2.920)

63. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, Musella A, D'amelio M, Cavallucci V, Martorana A, Bergamaschi A, Cencioni Mt, Butti E, Comi G, Bernardi G, Cecconi F, Battistini L, Furlan R, Martino G. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci. 2009 29:3442-52. (I.F. 7.490)

64. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK; Bioms Study Group. Altintas A, Bennett JL, Berven FS, Brundin L, Comabella M, Federiksen JL, Fleming JO, Franciotta D, Furlan R, Hintzen RQ, Johnson MH, Krasulova E, Kuhle J, Petzold A, Rajda C, Rejdak K, Van Pesch V, Waubant E. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 2009 35:117-27. (I.F. 4.852)

65. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. Meth. Mol. Biol. 2009 549:157-73.

66. Fazio R, Malosio ML, Lampasona, V, De Feo D, Privitera D, Marnetto F, Centonze D, Ghezzi A, Comi G, Furlan R, Martino G. Anti-acquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult. Scler. 2009 15:1153-63. (I.F. 3.312)

67. Rossi S, Furlan R, De Chiara V, Musella A, Lo Giudice T, Mataluni G, Cavasinni F, Cantarella C, Bernardi G, Muzio L, Martorana A, Martino G, Centonze D. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol. Dis. 2009 6:51-9. (I.F. 4.852)

68. Teunissen CC, Bennett JL, Berven FS, Comabella M, Franciotta D, Federiksen JL, Fleming J, Furlan R, Giovannoni G, Hintzen RQ, Johnson MH, Krasulova E, Kuhle JK, Magnone MC, Rajda C, Rejdak K, Schmidt HK, Van Pesch V, Wolf C, Tumani H, Hemmer B, Deisenhammer F. A consensus protocol for standardisation of CSF sampling and biobanking**.** Neurology. 2009 73:1914-1922. (I.F. 7.043)

69. Muzio L, Cavasinni F,; Marinaro C, Bergamaschi A, Bergami A, Porcheri C, Cerri F, Dina G, Quattrini A, Comi G, Furlan R*, Martino G. Cxcl10 enhances blood cells migration in the sub ventricular zone of mice affected by experimental autoimmune encephalomyelitis. Mol.Cell. Neurosci. 2009 43:268-80. (I.F. 3.934) * co-last

70. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G. The link between inflammation, synaptic transmission and neurodegeneration in Multiple Sclerosis. Cell Death & Diff. 2010 17:1083-1091 (I.F. 8.240)

71. Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia M, Martino G, Furlan R. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol. 2010 220:52-63. (I.F. 3.159)

72. Teunissen CE, Tumani HT, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant

E, Wolf C, Hemmer B, Deisenhammer F, Giovannoni G. Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Multiple Sclerosis. 2010 16:129-32. (I.F. 3.312)

73. De Santis G, Ferracin M, Biondani A, Caniatti L, Tola MR, Castellazzi M, Zagatti B, Battistini L, Borsellino G, Fainardi E, Gavioli R, Negrini M, Furlan R*, Granieri E. Altered miRNA expression in T regulatory cells in course of Multiple Sclerosis. J Neuroimmunol. 2010 226:165-71. (I.F. 3.159) * co-last

74. Rossi S, De Chiara V, Furlan R, Musella A, Cavasinni F, Muzio L, Bernardi G, Martino G, Centonze D. Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental Multiple Sclerosis. Brain, Behavior, and Immunity. 2010 24:1379-85. (I.F. 5.061)

75. Esposito M, Ruffini F, Bergami A, Garzetti L, Borsellino G, Battistini L, Martino G, Furlan R. IL-17 and IFN-γ secreting FoxP3^{+} T cells infiltrate the target tissue in experimental autoimmunity. J Immunol. 2010 185:7467-73 (I.F. 5.646).

76. Fazio R, Radaelli M, Furlan R. Neuromyelitis optica: concepts in evolution. J Neuroimmunol. 2011 231:100-4 (I.F. 3.159).

77. Ferrandi C , Richard F, Tavano P, Hauben E, Barbié V, Gotteland JP, Greco B, Fortunato M, Mariani MF, Furlan R, Comi G, Martino G, Zaratin PF. Characterization of immune cell subsets during active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Multiple Sclerosis. 2011 17:43-56. (I.F. 3.312)

78. Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, Musumeci G, Mandolesi G, De Ceglia R, Maida S, Biffi E, Pedrocchi A, Menegon A, Bernardi G, Furlan R, Martino G, Centonze D. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain, Behavior, and Immunity. 2011 25:947-56. (I.F. 5.061).

79. Farinazzo A, Gini B, Ruffini F, Milli A, Marconi S, Turano E, Cecconi D, Furlan R, Bonetti B. 2D immunomic approach for the study of IgG autoantibodies in the experimental model of multiple sclerosis. J Neuroimmunol. 2011 232:63-7. (I.F. 3.159).

80. Rossi S, Furlan R, De Chiara V, Muzio L, Musella A, Motta C, Studer V, Cavasinni F, Bernardi G, Martino G, Cravatt BF, Lutz B, Maccarrone M, Centonze D. Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis.Brain Behav Immun. 2011 25:1242-8. (I.F. 5.061).

81. Marinaro C, Butti E, Bergamaschi A, Papale A, Furlan R, Comi G, Martino G, Muzio L. In vivo fate analysis reveals the multipotent and self-renewal features of embryonic AspM expressing cells. PLoS One. 2011 6:e19419. (I.F. 4.351).

82. Teunissen C, Tumani H, Bennett J, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen J, Fleming J, Furlan R, Hintzen RQ, Hughes S, Jimenez CR, Johnson M, Krasulova E, Kuhle J, Magnone MG, Petzold A. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. MS Int. 2011 2011:246412

83. Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C, Grasso MG, Galgani S, Martinelli V, Comi G, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan G. T

regulatory cells are markers of disease activity in MS patients. PloS One. 2011 6:e21386 (I.F. 4.351)

84. Rossi S, Mancino R, Bergami A, Mori F, Castelli M, De Chiara V, Studer V, Mataluni G, Sancesario G, Parisi V, Kusayanagi H, Bernardi G, Nucci C, Bernardini S, Martino G, Furlan R, Centonze D. Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. Mult Scler. 2011 17:1301-12. (I.F. 3.312)

85. Luchetti A, Milani D, Ruffini F, Galli R, Falini A, Scotti G, Comi G, Martino G, Furlan R*, Politi L. Monoclonal antibodies conjugated with super-paramagnetic iron oxide particles allow MRI detection of lymphocytes in the mouse brain. Mol. Imaging. 2012 11:114-25. (I.F. 2.786) * co-last

86. Rossi S, Lo Giudice T, De Chiara V, Musella A, Studer V, Motta C, Bernardi G, Martino G, Furlan R, Martorana A, Centonze D. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol. 2012 165:861-9. (I.F. 4.925).

87. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, Musella A, Bergami A, Muzio L, Bernardi G, Battistini L, Martino G, Centonze D. Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012 71:76-83. (I.F. 10.746)

88. Caragnano M, Tortorella P, Bergami A, Ruggieri M, Livrea P, Specchio LM, Martino G, Trojano M, Furlan R, Avolio C. Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. J Neuroimmunol. 2012 245:93-7 (I.F. 2.901)

89. Privitera D, Corti V, Alessio M, Volontè A, Lampasona V, Comi G, Martino G, Franciotta D, Furlan R*, Fazio R. Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders. Neurol. Sci. 2013 34:313-20 (I.F. 1.220). *co-last

90. Morando S, Vigo T, Esposito M, Casazza S, Novi G, Principato MC, Furlan R, Uccelli A. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther. 2012 3:3. (I.F. 3.650)

91. Colombo E, Borgiani B, Verderio C, Furlan R. Microvesicles: novel biomarkers for neurological disorders. Front Physiol. 2012 3:63.

92. Turola E, Furlan R, Bianco F, Matteoli M, Verderio C. Microglial microvesicles secretion and intercellular signaling. Front Physiol. 2012 3:149.

93. Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, Riganti L, Corradini I, Francolini M, Garzetti L, Maiorino C, Servida F, Vercelli A, Dalla Libera D, Martinelli V, Comi G, Martino G, Matteoli M, Furlan R. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann. Neurol. 2012 72:610-624 (I.F. 11.089)

94. Maiorino C, Khorooshi RMH, Ruffini F, Løbner M, Bergami A, Garzetti L, Martino G, Owens T, Furlan R. IL-25 protects from neuroinflammation by modulating microglia. Gene Ther. 2013 20:487-496 (I.F. 4.538)

95. Grasselli G, Rossi S, Musella A, Gentile A, Loizzo S, Muzio L, Di Sanza C, Errico F, Musumeci F, Haji N, Fresegna D, Sepman H, De Chiara V, Furlan R, Martino G, Usiello A, Mandolesi G, Centonze D. Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. Br J Pharmacol. 2013 168:502-17. (I.F. 4.925).

96. Jolivel V, Luessi F, Masri J, Kraus S, Hubo M, Poisa-Beiro L, Paterka M, Klebow S, Yogev N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F, Waisman A. Modulation of dendritic cell properties by laquinimod as mechanism for modulating Multiple Sclerosis. Brain. 2013 136:1048-66. (I.F. 9.915)

97. Prada I, Furlan R, Matteoli M, Verderio C. Classical and unconventional secretory Pathways in microglia. Glia. 2013 61:1003-17. (I.F. 5.066)

98. Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler. 2013, PMID: 23836877 (I.F. 4.255)

99. Mori F, Nisticò R, Mandolesi G, Piccinin S, Mango D, Kusayanagi H, Berretta N, Bergami A, Gentile A, Musella A, Nicoletti CG, Nicoletti F, Buttari F, Mercuri NB, Martino G, Furlan R, Centonze D. Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis. NeuroMolecular Medicine. 2013 PMID: 23892937. (I.F. 4.492)

100. Rossi R, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, Sancesario G, Bernardini G, De Angelis G, Martino G, Furlan R, Centonze D. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult. Scler. J. 2013 PMID: 23886826. (I.F. 4.255)

101. Loiarro M, Volpe E, Ruggiero V, Gallo G, Furlan R, Maiorino C, Battistini L, Sette C. Mutational analysis identifies residues crucial for homodimerization of Myeloid Differentiation Factor 88 (MyD88) and for its function in immune cells. J. Biol. Chem. 2013 288:30210-22. (I.F. 4.651)

102. Joshi P, Turola E, Ruiz A, Bergami A, Dalla Libera D, Benussi L, Giussani P, Magnani G, Comi G, Ghidoni R, Legname G, Furlan R, Matteoli M, Verderio C. Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2013 doi: 10.1038/cdd.2013.180 (I.F. 8.371)

103. Della-Torre E, Passerini G, Furlan R, Roveri L, Chieffo R, Anzalone N, Doglioni C, Zardini E, Sabbadini MG, Franciotta D. Cerebrospinal Fluid Analysis in Immunoglobulin G4-related Hypertrophic Pachymeningitis. J Rheumatol. 2013 40:1927-9. (I.F. 3.260)

104. Cesani M, Cavalca E, Macco R, Leoncini G, Terreni MR, Lorioli L, Furlan R, Comi G, Doglioni C, Zacchetti D, Sessa M, Scherzer CR, Biffi A. Metallothioneins as Dynamic Markers for Brain Disease in Lysosomal Disorders. Ann.Neurol. 2013 doi: 10.1002/ana.24053 (I.F. 11.93)

105. Greco R, Bondanza A, Vago L, Moiola L, Rossi P, Furlan R, Martino G, Radaelli M, Martinelli V, Carbone MR, Lupo Stanghellini MT, Assanelli A, Bernardi M, Corti C, Peccatori J, Bonini C, Vezzulli P, Falini A, Ciceri F, Comi G. Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann. Neurol. 2013 doi: 10.1002/ana.24079. (I.F. 11.93)

106. Garzetti L, Menon R, Finardi A, Bergami A, Sica A, Martino G, Comi G, Verderio C, Farina C, Furlan R. Activated macrophages release microvesicles containing polarized M1 or M2 mRNAs. J Leuk Biol. 2013 PMID: 24379213 (I.F. 4.568)

107. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, Furlan R. Oxidative stress is differentially present in multiple sclerosis courses, early evident and unrelated to treatment. J Immunol Res. 2014:961863. doi: 10.1155/2014/961863. (I.F. 3.064)

108. Rossi S, Studer V, Motta C, Germani G, Macchiarulo G, Buttari F, Mancino R, Castelli M, De Chiara V, Weiss S, Martino G, Furlan R, Centonze D. Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in Multiple Sclerosis. J Neuroinflamm. 2014 11:32. doi: 10.1186/1742-2094-11-32. (I.F. 4.350)

109. Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N, Rambaldelli G, Tansella M, Finardi AM, Martino G, Perlini C, Furlan R. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry. 2014 Jul 1;4:e406. doi: 10.1038/tp.2014.46. (I.F. 5.538)

110. Sardi C, Zambusi L, Finardi A, Ruffini F, Tolun AA, Dickerson IM, Righi M, Zacchetti D, Grohovaz F, Provini L, Furlan R, Morara S. Involvement of Calcitonin Gene-Related Peptide and Receptor Component Protein in experimental autoimmune encephalomyelitis. J Neurimmunol. 2014 Jun 15;271(1-2):18-29. doi: 10.1016/j.jneuroim.2014.03.008 (I.F. 3.014)

111. Mori F, Nicoletti CG, Rossi S, Motta C, Kusayanagi H, Bergami A, Studer V, Buttari F, Barbieri F, Weiss S, Nisticò R, Martino G, Furlan R, Centonze D. Growth Factors and Synaptic Plasticity in relapsing-remitting Multiple Sclerosis. Neur Mol Med. 2014 Jun;16(2):490-8. doi: 10.1007/s12017-014-8297-7 (I.F. 4.492)

112. Cianciaruso C, Pagani A, Martelli C, Bacigaluppi M, Squadrito ML, Dico AL, De Palma M, Furlan R, Lucignani G, Falini A, Biffi A, Ottobrini L, Politi LS. Cellular magnetic resonance with iron oxide nanoparticles: long-term persistence of SPIO signal in the CNS after transplanted cell death. Nanomedicine (Lond). 2014 May 13:1-18. (I.F. 5.260)

113. Rossi S, Motta C, Studer V, Rocchi C, Macchiarulo G, Barbieri F, Marfia GA, Furlan R, Martino G, Mancino R, Centonze D. Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis. Mult Scler. 2014 May 29. pii: 1352458514537365. (I.F. 4.255)

114. Agosta F, Dalla Libera D, Gioele Spinelli E, Finardi A, Canu E, Bergami A, Bocchio Chiavetto L, Baronio M, Comi G, Martino G, Matteoli M, Magnani G, Verderio C, Furlan R. Myeloid microvesicles in CSF are associated with myelin damage and neuronal loss in mild cognitive impairment and alzheimer disease. Ann. Neurol. 2014 doi: 10.1002/ana.24235. (I.F. 11.193)

115. Montarolo F, Raffaele C, Perga S, Martire S, Finardi A, Furlan R, Hintermann S, Bertolotto A. Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mouse. PloS One. 2014 9(9):e108791. doi: 10.1371/journal.pone.0108791. (I.F. 3.534)

116. Arnò B, Grassivaro F, Rossi C, Bergamaschi A, Castiglioni V, Furlan R, Greter M, Favaro R, Comi G, Becher B, Martino G, Muzio L. Neural progenitor cells orchestrate microglia migration and positioning into the developing cortex. Nat Commun. 2014 Nov 26;5:5611. doi: 10.1038/ncomms6611. (I.F. 10.742)

117. Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F, Ruocco G, Buttari F, Finardi A, Mancino R, Weiss S, Battistini L, Martino G, Furlan R, Drulovic J, Centonze D. Interleukin-1beta causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol. Neurodeg. 2014 12;9:56. doi: 10.1186/1750-1326-9-56 (I.F. 5.290)

118. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier U, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Zborníková P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson HB, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martinez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Colombo E, Franciotta D, Derfuss T, Lindberg RLP, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar L, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan S, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. MSJ. 2015 Feb 13. pii: 1352458514568827. (I.F. 4.863)

119. Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, Furlan R, Martino G, Centonze D. Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler. 2015 Jan 12. pii: 1352458514564482. (I.F. 4.255)

120. Joshi P, Benussi L, Furlan R, Ghidoni R, Verderio C. Extracellular Vesicles in Alzheimer's Disease: Friends or Foes? Focus on Aβ-Vesicle Interaction. Int. J. Mol. Sci. 2015 16 4800-4813. (I.F. 2.721).

121. Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, Gasperini C, Furlan R, Centonze D, Battistini L, Volpe E. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. Clin. Sci. 2015 29:291-303. doi: 10.1042/CS20140608 (I.F. 5.629)

122. Carandini T, Colombo F, Finardi A, Casella G, Garzetti L, Verderio C, Furlan R. Microvesicles: what is the role in multiple sclerosis? Front. Neurol. 2015 26,6:111. doi: 10.3389/fneur.2015.00111.

123. Graziano F, Desdouits M, Garzetti L, Podini P, Alfano M, Rubartelli A, Furlan R, Benaroch P, Poli G. Extracellular ATP induces the rapid release of HIV-1from virus containing compartments of human macrophages. PNAS. 2015 112(25):E3265-73. doi: 10.1073/pnas.1500656112 (I.F. 9.809)

124. Prada I, Amin L, Furlan R, Legname G, Verderio C, Cojoc D. A new approach to follow single extracellular vesicle-cell interaction using optical tweezers. Biotechniques. 2016

60:35-41 (I.F. 2.754)

125. Penton-Rol G, Lagumersindez-Denis N, Muzio L, Bergami A, Furlan R, Fernández-Masso JR, Nazabal-Galvez M, Llópiz-Arzuaga A, Herrera-Rolo T, Veliz-Rodriguez T, Polentarutti N, Marín-Prida J, Raíces-Cruz I, Valenzuela-Silva C, Martins Teixeira M, Pentón-Arias E. Comparative neuroregenerative effects of c-phycocyanin and IFN-beta in a model of multiple sclerosis in mice. J Neuroimmune Pharmacology. 2016 11:153-67 (I.F. 4.110)

126. Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B, Peferoen-Baert R, van der Valk P, Garlanda C, Kipp M, Furlan R, van Noort JM, Amor S. Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate the autoimmune neuroinflammation. Eur J Immunol. 2016 46:701-11 (I.F. 4.03)

127. Passerini G, Dalla Costa G, Sangalli F, Moiola L, Colombo B, Locatelli M, Comi G, Furlan R, Martinelli V. Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. Mult Scler Int. 2016. 2016:2303857. doi: 10.1155/2016/2303857. (I.F. 2.2)

128. Fais S, Borras F, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T, Furlan R, Hendrix A, Gursel I, Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, Marcilla A, Marei S, Llorente A, Nazarenko I, O'Driscoll L, Oliveira C, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos H, Yáñez-Mó M, Yliperttula ML, Zarovni N, Zavec AB, Giebel B. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano. 2016 10:3886-99. (I.F. 12.881)

129. Ferrara G, Errede M, Girolamo F, Morando S, Ivaldi F, Panini N, Bendotti C, Perris R, Furlan R, Virgintino D, Kerlero de Rosbo N, Uccelli A. NG2, a common denominator for neuroinflammation, blood-brain barrier alteration and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation. Acta Neuropath. 2016 132:23-42. doi: 10.1007/s00401-016-1563-z. (I.F. 10.762)

130. Rizzo R, Bortolotti D, Fainardi E, Gentili V, Bolzani S, Baldi E, Casetta I, Granieri E, Rotola A, Furlan R, Di Luca D. KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in Multiple Sclerosis patients. J Neuroimmunol. 2016 294:1-5. (I.F. 2.467)

131. Casella G, Garzetti L, Gatta AT, Finardi A, Maiorino C, Ruffini F, Martino G, Muzio L, Furlan R. IL4 induces IL6 producing M2 macrophages associated to inhibition of neuroinflammation in vitro and in vivo. J Neuroinflamm. 2016 13:139. (I.F. 4.667)

132. Mori F, Nisticò R, Nicoletti CG, Zagaglia S, Mandolesi G, Piccinin S, Martino G, Finardi A, Rossini PM, Marfia GA, Furlan R, Centonze D. RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. Mult Scler. 2016 11:1405-1412. (I.F. 4.671)

133. Lecca D, Marangon D, Coppolino G, Menendez Mendez A, Finardi A, Dalla Costa G, Martinelli V, Furlan R, Abbracchio M. MiR-125a-3p timely inhibits oligodendroglial maturation and is pathologically up-regulated in human multiple sclerosis. Scientific Reports. 2016 6: 34503 (I.F. 5.228)

134. Dobson R, Kuhle J, Middeldorp J, Giovannoni G, on behalf of the International CIS study investigators. Neurol Neuroimmunol Neuroinflamm 2017,4:e318, doi: 10.1212/NXI.0000000000000318.

135. Srinivasan S, Di Dario M, Russo A, Menon R, Brini E, Romeo M, Sangalli F, Dalla Costa G, Rodegher M, Radaelli M, Moiola L, Cantarella D, Medico E, Martino G, Furlan R, Martinelli V, Comi G, Farina C. Dysregulation of multiple sclerosis risk genes and pathways at distinct stages of disease. Neuroimmunology and Neuroinflammation. 2017 Mar 16,4(3):e337. doi: 10.1212/NXI.0000000000000337.

136. Martinelli V, Dalla Costa G, Messina MJ, Di Maggio G, Sangalli F, Moiola L, Rodegher M, Colombo B, Furlan R, Leocani L, Falini A, Comi G. Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. Acta Neurol. Sc. 2017 136:454-461 DOI:10.1111/ane.12761 (I.F. 2.559)

137. Srinivasan S, Severa M, Rizzo F, Menon R, Brini E, Mechelli R, Martinelli V, Hertzog P, Salvetti M, Furlan R, Martino G, Comi G, Coccia E, Farina C. Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis. Sci Rep. 2017 7:8981. doi: 10.1038/s41598-017-09286-y. (I.F. 4.259)

138. Rossi S, Studer V, Motta C, Polidoro S, Perugini J, Macchiarulo G, Giovannetti AM, Pareja-Gutierrez L, Calò A, Colonna I, Furlan R, Martino G, Centonze D. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology. 2017 26,89(13):1338-1347. doi: 10.1212/WNL.0000000000004411. (I.F. 8.320)

139. Guarnieri FC, Bellani S, Yekhlef L, Bergamaschi A, Finardi A, Fesce R, Pozzi D, Monzani E, Fornasiero EF, Matteoli M, Martino G, Furlan R, Taverna S, Muzio L, Valtorta F. Synapsin I deletion reduces neuronal damage and ameliorates clinical progression of experimental autoimmune encephalomyelitis. Brain Behav. Imm. 2017 pii: S0889-1591(17)30474-9. doi: 10.1016/j.bbi.2017.10.018 (I.F. 5.964)

140. Stampanoni Bassi M, Garofalo S, Marfia GA, Gilio L, Simonelli I, Finardi A, Furlan R, Sancesario GM, Di Giandomenico J, Storto M, Mori F, Centonze D, Iezzi E. Amyloid-β homeostasis bridges inflammation, synaptic plasticity deficits and cognitive dysfunction in multiple sclerosis. Frontiers in Molecular Neuroscience. Doi: 10.3389/fnmol.2017.00390. (I.F. 3.566)

141. Dalla Costa G, Finardi A, Garzetti L, Carandini T, Comi G, Martinelli V, Furlan R. Disease modifying treatments modulate myeloid cells in multiple sclerosis patients. Neu Sci. 2017 doi: 10.1007/s10072-017-3176-2 (I.F. 1.749)

142. Croese T, Furlan R. Extracellular vesicles in neurodegenerative diseases. Molecular Aspects in Medicine. doi: 10.1016/j.mam.2017.11.006 (I.F. 7.344)

143. Casella G, Finardi A, Descamps H, Colombo F, Maiorino C, Ruffini F, Patrone M, Degano M, Martino G, Muzio L, Becher B, Furlan R. IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression. Scientific Reports. 2017 7:16547. doi: 10.1038/s41598-017-16702-w (I.F. 4.259)

144. Monteleone F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, Buttari F, Furlan R, Finardi A, Marfia GA, Centonze D, Mori F Nerve growth factor is elevated in the CSF of patients with

multiple sclerosis and central neuropathic pain. J Neuroimmunol. 2018 314:89-93. doi: 10.1016/j.jneuroim.2017.11.012. (I.F. 2.720)

145. Rossi C, Cusimano M, Zambito M, Finardi A, Capotondo A, Garcia-Manteiga JM, Comi G, Furlan R, Martino G, Muzio L. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of Amyotrophic Lateral Sclerosis. Cell Death & Dis. 2018 9:250. doi: 10.1038/s41419-018-0288-4. (I.F. 5.965)

146. Prada I, Gabrielli M, Turola E, Iorio A, D'Arrigo G, Parolisi R, De Luca M, Pacifici M, Bastoni M, Lombardi M, Legname G, Cojoc D, Buffo A, Furlan R, Peruzzi F, Verderio C. Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underlying inflammation-induced synaptic alterations. Acta Neuropathol. 2018 doi: 10.1007/s00401-017-1803-x. (I.F. 12.213)

147. Colombo F, Bastoni M, Nigro A, Podini P, Finardi A, Casella G, Ramesh M, Farina C, Verderio C, Furlan R. Cytokines stimulate the release of microvesicles from myeloid cells independently from the P2X7-receptor/acid sphingomyelinase pathway. Front. Immunol. 2018 doi: 10.3389/fimmu.2018.00204 (I.F. 6.429)

148. Lecca D, Coppolino GT, Marangon D, Menichetti G, Fumagalli M, Dimou L, Furlan R, Abbracchio MP. Differential local tissue permissiveness influences the final fate of GPR17-expressing oligodendrocyte precursors in two distinct models of demyelination. Glia. 2018 doi: 10.1002/glia.23305. (I.F. 6.2)

149. Mango D, Nisticò R, Furlan R, Finardi A, Centonze D, Mori F. PDGF Modulates Synaptic Excitability and Short-Latency Afferent Inhibition in Multiple Sclerosis. Neurochem Res. 2018 Feb 1. doi: 10.1007/s11064-018-2484-0 (I.F. 2.125)

150. Stampanoni Bassi M, Iezzi E, Marfia GA, Simonelli I, Musella A, Mandolesi G, Fresegna D, Pasqualetti P, Furlan R, Finardi A, Mataluni G, Landi D, Gilio L, Centonze D, Buttari F. Platelet-derived growth factor predicts prolonged relapse-free period in Multiple Sclerosis J Neuroinflamm. 2018 15:108. doi: 10.1186/s12974-018-1150-4. (I.F. 5.717)

151. Coppolino GT, Marangon D, Negri C, Menichetti G, Fumagalli M, Gelosa P, Dimou L, Furlan R, Lecca D, Abbracchio MP. Differential local tissue permissiveness influences the final fate of GPR17-expressing oligodendrocyte precursors in two distinct models of demyelination. Glia. 2018 66:1118-1130. doi: 10.1002/glia.23305. (I.F. 5.846).

152. Casella G, Colombo F, Finardi A, Ill-Ragaa G, Spinelli A, Podini P, Bastoni M, Descamps H, Muzio L, Furlan R. Phagocytes-targeted extracellular vesicles containing IL4 inhibit neuroinflammation in a mouse model of multiple sclerosis. Mol. Ther. 2018 26:2107-2118. doi: 10.1016/j.ymthe.2018.06.024. (I.F. 7.008).

153. Rossetti I, Zambusi L, Finardi A, Bodini A, Provini L, Furlan R, Morara S. Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018 323:94-104. doi: 10.1016/j.jneuroim.2018.07.005 (I.F. 2.655).

154. Stampanoni Bassi M, Iezzi E, Landi D, Monteleone F, Gilio L, Simonelli I, Musella A, Mandolesi G, De Vito F, Furlan R, Finardi A, Marfia GA, Centonze D, Buttari F. Delayed

treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. J Neurol. 2018 doi: 10.1007/s00415-018-8994-5. (I.F. 3.783)

155. Chiriacò MS, Bianco M, Nigro A, Primiceri E, Ferrara F, Romano A, Quattrini A, Furlan R, Arima V, Maruccio G. Lab-on-Chip for Exosomes and Microvesicles Detection and Characterization. Sensors (Basel). 2018 18(10). pii: E3175. doi: 10.3390/s18103175. (I.F. 2.475)

156. Becher J, Simula L, Volpe E, Procaccini C, La Rocca C, D'Acunzo P, Cianfanelli V, Strappazzon F, Caruana I, Nazio F, Weber G, Gigantino V, Botti G, Ciccosanti F, Borsellino G, Campello S, Mandolesi G, De Bardi M, Fimia GM, D'Amelio M, Ruffini F, Furlan R, Centonze D, Martino G, Braghetta P, Chrisam M, Bonaldo P, Matarese G, Locatelli F, Battistini L, Cecconi F. AMBRA1 controls regulatory T-cell differentiation and homeostasis upstream of the FOXO3-FOXP3 axis. Developmental Cell 47, 592–607, doi.org/10.1016/j.devcel.2018.11.010 (I.F. 9.616)

157. Dalla Costa G, Martinelli V, Sangalli F, Moiola L, Colombo B, Radaelli M, Leocani L, Furlan R, Comi G. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology 2019 doi: 10.1212/WNL.0000000000006902. (I.F. 8.055)

158. Stampanoni Bassi M, Gentile A, Iezzi E, Zagaglia S, Musella A, Simonelli I Gilio L, Furlan R, Finardi A, Girolama Marfia A, Guadalupi L, Bullitta S, Mandolesi G, Centonze D, Buttari F. Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis.
Frontiers in Neurology. I10:30. doi: 10.3389/fneur.2019.00030 (I.F. 3.508)

159. Gastaldi M, De Rosa A, Maestri M, Zardini E, Scaranzin S, Guida M, Borrelli P, Ferraro OE, Lampasona V, Furlan R, Irani SR, Waters P, Lang B, Vincent A, Marchioni E, Ricciardi R, Franciotta D. Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study. Eur. J. Neurol. https://doi.org/10.1111/ene.13922 (I.F. 4.621).

160. Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G. Serum neurofilaments increase at PML onset in natalizumab-treated MS patients. Ann Neurol. 2019 85:606-610. doi: 10.1002/ana.25437 (I.F. 10.25)

161. Vergara D, Nigro A, Romano A, De Domenico S, Damato M, Franck J, Coricciati C, Wistorski M, Fournier I, Quattrini A, Salzet M, Furlan R, Maffia M. Distinct protein expression networks are activated in microglia cells after stimulation with INF-γ and IL-4. Cells. 2019 doi:10.3390/cells8060580 (I.F. 4.829)

162. Stampanoni Bassi M, Iezzi E, Buttari F, Gilio L, Simonelli I, Carbone F, Micillo T, De Rosa V, Sica F, Furlan R, Finardi A, Fantozzi R, Storto M, Bellantonio P, Pirollo P, Di Lemme S, Musella A, Mandolesi G, Centonze D, Matarese G. Obesity worsens central inflammation and disability in multiple sclerosis. Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473. (I.F. 5.280)

163. Dalla Costa G, Martinelli V, Furlan R, Comi G. Reply to: "Serum Neurofilaments as candidate biomarkers of natalizumab-PML". Ann Neurol. 2019 Jun 11. doi: 10.1002/ana.25526. (I.F. 10.25)

164. Furlan R, Melloni E, Finardi A, Vai B, Di Toro S, Aggio V, Battistini L, Borsellino G, Manfredi E, Falini A, Colombo C, Poletti S, Benedetti F. Natural Killer cells protect white matter integrity in Bipolar Disorder. Brain Behav Immun. 2019 doi: 10.1016/j.bbi.2019.06.037. (I.F. 6.170)

165. Stampanoni Bassi M, Iezzi E, Mori F, Simonelli I, Gilio L, Buttari F, Sica F, De Paolis N, Mandolesi G, Musella A, De Vito F, Dolcetti E, Bruno A, Furlan R, Finardi A, Marfia GA, Centonze D, Rizzo FR. Interleukin-6 disrupts synaptic plasticity and impairs tissue damage compensation in Multiple Sclerosis. Neurorehab. & Neural Repair. 2019 20:1545968319868713. doi: 10.1177/1545968319868713 (I.F. 3.757)

166. Gironi M , Dalla-Costa G , Frigo M , Rovaris M , Clerici M , Bazzini C , Andreoni S , Comi G , Furlan R , Ferrarese C , Cavaletti G , Saresella M , Zoia CP Platelet glutamate uptake and Th1 cells inversely correlate in relapsing/remitting and in progressive multiple sclerosis. Mult Scler Relat Disord. 2020 41:102007. doi: 10.1016/j.msard.2020.102007 (I.F. 2.725)

167. Benedetti F, Aggio V, Pratesi ML, Greco G, Furlan R. Neuroinflammation in Bipolar Depression. Front Psychiatry. 2020 11:71. doi: 10.3389/fpsyt.2020.00071. eCollection 2020. (I.F. 3.532)

168. Amoruso A, Blonda M, Gironi M, Grasso R, Di Francescantonio V, Scaroni V, Furlan R, Verderio C, Avolio C. Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients. Sci Rep. 2020 10(1):6125. doi: 10.1038/s41598-020-63282-3.. (I.F. 4.122)

169. Stampanoni Bassi M, Iezzi E, Drulovic J, Pekmezovic T, Gilio L, Furlan R, Finardi A, Marfia GA, Sica F, Centonze D, Buttari F. IL-6 in the cerebrospinal fluid signals disease severity in multiple sclerosis. Front Cell Neurosci. 2020 Jun 23,14:120. doi: 10.3389/fncel.2020.00120 (I.F. 4.555)

170. Motta C, Finardi A, Toniolo S, Di Lorenzo F, Scaricamazza E, Loizzo S, Mercuri NB, Furlan R, Koch G, Martorana A. Protective role of cerebrospinal fluid inflammatory cytokines in patients with amnestic mild cognitive impairment and early Alzheimer's disease carrying Apolipoprotein E4 genotype. J Alzheimers Dis. 2020,76(2):681-689. doi: 10.3233/JAD-191250 (I.F. 3.517)

171. Finardi A, Diceglie M, Carbone L, Arnò C, Mandelli A, De Santis G, Fedeli M, Dellabona P, Casorati G, Furlan R. miR106b-25 and miR17-92 are crucially involved in the development of experimental neuroinflammation**.** Frontiers in Neurology. 2020 11:912. doi: 10.3389/fneur.2020.00912. (I.F. 3.552)

172. Kapoor R, Smith KE, Allegretta M, Arnold DL, Carroll W, Comabella M, Furlan R, Harp C, Kuhle J, Leppert D, Plavina T, Sellebjerg F, Sincock C, Teunissen CE, Topalli I, von Raison F, Walker E, Fox RJ. Serum Neurofilament Light as a Biomarker in Progressive Multiple Sclerosis. Neurology. Neurology. 2020 doi: 10.1212/WNL.0000000000010346. (I.F. (8.689)

173. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere Querini P, Benedetti F. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Imm. 30:S0889-1591, 31606-8. doi: 10.1016/j.bbi.2020.07.037 (I.F. 6.633)

174. Poletti S, Vai B, Mazza MG, Zanardi R, Lorenzi C, Calesella F, Cazzetta S, Branchi I, Colombo C, Furlan R, Benedetti F. A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach. Prog Neuropsychopharmacol Biol Psychiatry. 2020 doi: 10.1016/j.pnpbp.2020.110136. (I.F. 4.361)

175. Stampanoni Bassi M, Buttari F, Gabri Nicoletti C, Mori F, Gilio L, Simonelli I, De Paolis N, Marfia GA, Furlan R, Finardi A, Centonze D, Iezzi E. Interleukin-1β alters Hebbian synaptic plasticity in multiple sclerosis. Int. J Mol. Sci. 2020 21(19):E6982. doi: 10.3390/ijms21196982. (I.F. 4.556)

176. Engel S, Jolivel V, Kraus SHP, Zayoud M, Rosenfeld K, Tumani H, Furlan R, Kurschus FC, Waisman A, Luessi F. Laquinimod dampens IL-1β signaling and Th17 polarizing capacity of monocytes in MS patients. Neuroimmunology & Neuroinflammation. 2020 Nov 17;8(1):e908. doi: 10.1212/NXI.0000000000000908. (I.F. 7.724)

177. Benedetti F, Poletti S, Vai B, Mazza MG, Lorenzi C, Brioschi S, Aggio V, Branchi I, Colombo C, Furlan R, Zanardi R. Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder. Eur Neuropsychopharmacol. 2020 doi: 10.1016/j.euroneuro.2020.11.009 (I.F. 3.853)

178. Stampanoni Bassi M, Buttari F, Simonelli I, Gilio L, Furlan R, Finardi A, Marfia GA, Visconti A, Paolillo A, Storto M, Gambardella S, Ferese R, Salvetti M, Uccelli A, Matarese G, Centonze D, De Vito F. A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: implications for cladribine treatment. Genes (Basel). 2020 Sep 30;11(10):1152. doi: 10.3390/genes11101152 (I.F. 3.759).

179. Fumagalli F, Olivari D, Boccardo A, De Giorgio D, Affatato R, Ceriani S, Bariselli S, Sala G, Cucino A, Zani D, Novelli D, Babini G, Magliocca A, Russo I, Staszewsky L, Salio M, Lucchetti J, Maisano AM, Fiordaliso F, Furlan R, Gobbi M, Luini MV, Pravettoni D, Scanziani E, Belloli A, Latini R, Ristagno G. Ventilation with argon improves survival with good neurological recovery after prolonged untreated cardiac arrest - an experimental study. JAHA 2020. doi: 10.1161/JAHA.120.016494 (I.F. 4.45).

180. Colombo F, Casella G, Podini P, Finardi A, Racchetti G, Norton E.G., Cocucci E., Furlan R. Polarized cells display asymmetric 1 release of extracellular vesicles. Traffic 2020 doi: 10.1111/tra.12775. (I.F. 4.400)

181. Marostica G, Gelibter S, Gironi M, Nigro A, Furlan R. Extracellular Vesicles in Neuroinflammation. Front Cell Dev Biol 2021. 8:623039. doi: 10.3389/fcell.2020.623039 (I.F. 5.180)

182. Enrico P, Delvecchio G, Turtulici N, Pigoni A, Villa FM, Perlini C, Rossetti MG, Bellani M, Lasalvia A, Bonetto C, Scocco P, D'Agostino A, Torresani S, Imbesi M, Bellini F, Veronese A, Bocchio L, Gennarelli M, Balestrieri M, Colombo G, Finardi A, Ruggeri M, Furlan R, Brambilla P. Classification of psychoses based on immunological features: a machine learning study in a large cohort of first-episode and chronic patients. Schizophrenia Bullettin 2021 doi: 10.1093/schbul/sbaa190. (I.F. 7.958)

183. Furlan R. A tolerizing mRNA vaccine against autoimmunity? Mol Ther 2021 doi: 10.1016/j.ymthe.2021.02.03 (I.F. 8.402)

184. Gelibter S, Pisa M, Croese T, Dalla Costa G, Orrico M, Preziosa P, Sangalli F, Martinelli V, Furlan R, Filippi M. Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis? J Neurol. 2021 doi: 10.1007/s00415-020-10322-7. (I.F. 3.783)

185. Dalla Costa G, Croese T, Pisa M, Finardi A, Fabbella L, Martinelli V, Leocani L, Filippi M, Comi G, Furlan R. CSF extracellular vesicles and risk of disease activity after a first demyelinating event. MS Journal. 2021 doi: 10.1177/1352458520987542 . (I.F. 5.412)

186. Mandolesi G, Rizzo FR, Balletta S, Stampanoni Bassi M, Gilio L, Guadalupi L, Nencini M, Moscatelli A, Ryan CP, Licursi V, Dolcetti E, Musella A, Gentile A, Fresegna D, Bullitta S, Caioli S, Vanni V, Sanna K, Bruno A, Buttari F, Castelli C, Presutti C, De Santa F, Finardi A, Furlan R, Centonze D, De Vito F. The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis. Cells. 2021 10(2):330. doi: 10.3390/cells10020330. (I.F. 4.366)

187. Nigro A, Finardi A, Ferraro MM, Manno DE, Quattrini A, Furlan R, Romano A. Selective loss of microvesicles is a major issue of the differential centrifugation isolation protocols. Sci Rep. 2021 11(1):3589. doi: 10.1038/s41598-021-83241-w. (I.F. 3.988)

188. Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, Belloni C, Steffanoni S, Gulino A, Anghileri E, Diffidenti A, Finardi A, Gagliardi F, Anzalone N, Nonis A, Furlan R, De Lorenzo D, Terreni MR, Martinelli V, Sassone M, Foppoli M, Angelillo P, Guggiari E, Falini A, Mortini P, Filippi M, Tarantino V, Eoli M, Ciceri F, Doglioni C, Tripodo C, Locatelli M, Cangi MG, Ponzoni M. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol. 2021 doi: 10.1111/bjh.17357. (I.F. 5.518)

189. Pisa M, Croese T, Dalla Costa G, Guerrieri S, HuangS, Sangalli F, Colombo B, Moiola L, Martinelli V, Comi G, Furlan R, Leocani L. Asymptomatic anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. Brain. 2021 144:848-862. doi: 10.1093/brain/awaa458. (I.F. 11.337)

190. Dalla Bella E, Bersano E, Antonini G, Borghero G, Capasso M, Caponnetto C, Chiò A, Corbo M, Filosto M, Giannini F, Spataro R, Lunetta C, Mandrioli J, Messina S, Monsurrò MR, Mora G, Riva N, Rizzi R, Siciliano G, Silani V, Simone I, Sorarù G, Tugnoli V, Verriello L, Volanti P, Furlan R, Nolan JM, Abgueguen E, Tramacere I, Lauria G. The Unfolded Protein Response in Amyotrophic Later Sclerosis: Results of a Phase 2 Trial. Brain 2021 doi: 10.1093/brain/awab167. (I.F. 11.337)

191. De Lorenzo R, Loré N, Finardi A, Mandelli A, Cirillo DM, Tresoldi C, Benedetti F, Ciceri F, Rovere-Querini P, Comi G, Filippi M, Manfredi AA, Furlan R. Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol. 2021 doi: 10.1007/s00415-021-10595-6. (I.F. 3.956)

192. Santangelo R, Agosta F, Masi F, Spinelli EG, Cecchetti G, Caso F, Cardamone R, Barbieri A, Furlan R, Magnani G, Filippi M. Serum neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer's disease. Eur J Neurol. 2021 doi: 10.1111/ene.14999. (I.F. 4.387)

193. Simon MS, Schiweck C, Arteaga-Henríquez G, Poletti S, Haarman BCM, Dik WA, Schwarz M,Vrieze E, Mikova O, Joergens S, Musil R, Claes S, Baune BT, Leboyer M, Benedetti F,

Furlan R, Berghmans R, de Wit H, Wijkhuijs A, Arolt V, Müller N, Drexhage HA. Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021 /doi.org/10.1016/j.pnpbp.2021.110391 (I.F.4.361)

194. Gelibter S Pisa M, Croese T, Finardi A, Mandelli A, Sangalli F, Colombo B, Martinelli V, Comi G, Filippi M, Furlan R. Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis. Ann. Neurol. 2021 DOI:10.1002/ana.26154. (I.F. 9.037)

195. Fedeli M, Kuka M, Finardi A, Albano F, Viganò V, Olson EN, Iannacone M, Furlan R, Dellabona P, Casorati G. miR-21 sustains CD28-signalling and low affinity T-cell responses at the expense of self-tolerance. Clinical & Translational Immunology 2021. 10(9):e1321. doi: 10.1002/cti2.1321. (I.F. 6.661)

196. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, Ciceri F; COVID-19 BioB Outpatient Clinic Study group, Rovere-Querini P, Benedetti F. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021 94:138-147. doi: 10.1016/j.bbi.2021.02.021. (I.F. 7.217)

197. Stampanoni Bassi M, Gilio L, Iezzi E, Moscatelli A, Pekmezovic T, Drulovic J, Furlan R, Finardi A, Mandolesi G, Musella A, Galifi G, Fantozzi R, Bellantonio P, Storto M, Centonze D, Buttari F. Age at disease onset associates with oxidative stress, neuroinflammation and impaired synaptic plasticity in relapsing remitting multiple sclerosis. Front Aging Neurosci. doi.org/10.3389/fnagi.2021.694651 (I.F. 4.504)

198. Siracusano G, Finardi A, Pastori C, Martinelli V, Furlan R, Lopalco L. HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model. Front Immunol. 2021 12:771359. doi: 10.3389/fimmu.2021.771359. eCollection 2021. (I.F. 6.429)

199. Poletti S, Palladini M, Mazza MG, De Lorenzo R; COVID-19 BioB Outpatient Clinic Study group, Furlan R, Ciceri F, Rovere-Querini P, Benedetti F. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life. Eur Arch Psychiatry Clin Neurosci. 2021 26:1-10. doi: 10.1007/s00406-021-01346-9. (I.F. 3.525)

200. Lorè NI, De Lorenzo R, Rancoita PMV, Cugnata F, Agresti A, Benedetti F, Bianchi ME, Bonini C, Capobianco A, Conte C, Corti A, Furlan R, Mantegani P, Maugeri N, Sciorati C, Saliu F, Silvestri L, Tresoldi C; Bio Angels for COVID-BioB Study Group, Ciceri F, Rovere-Querini P, Di Serio C, Cirillo DM, Manfredi AA. CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. Mol Med. 2021 27:129. doi: 10.1186/s10020-021-00390-4. (I.F. 6.354)

201. Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Mult Scler. 2021 30:13524585211035318. doi: 10.1177/13524585211035318. (I.F. 5.412)

202. Aggio V, Fabbella L, Mazza E, Finardi A, Colombo C, Benedetti F, Furlan R. Neurofilaments light: Possible biomarker of brain modifications in bipolar disorder. J Affect Disord. 2022 300:243-248. doi: 10.1016/j.jad.2021.12.122. (I.F. 4.839)

203. Mazza MG, Palladini M, De Lorenzo R, Bravi B, Poletti S, Furlan R, Ciceri F; COVID-19 BioB Outpatient Clinic Study group, Rovere-Querini P, Benedetti F. One-year mental health outcomes in a cohort of COVID-19 survivors. J Psychiatr Res. 2021 145:118-124. doi: 10.1016/j.jpsychires.2021.11.031. (I.F. 4.465)

204. Moiola L, Riva A, Nicoletti F, Uccelli A, Salvetti M, Battistini L, Furlan R. Vaccination opportunities in multiple sclerosis patients treated with cladribine tablets.Curr Neuropharmacol. 2021 doi: 10.2174/1570159X20666211217160451.(I.F. 7.363)

205. Gelibter S, Marostica G, Mandelli A, Siciliani S, Podini P, Finardi A, Furlan R. The impact of storage on extracellular vesicles: a systematic study. J Extracell Vesicles. 2022 11(2):e12162. doi: 10.1002/jev2.12162 (I.F. 25.841)

206. Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022 59:103535. doi: 10.1016/j.msard.2022.103535. (I.F. 5.412)

207. Wihersaari L, Reinikainen M, Furlan R, Mandelli A, Vaahersalo J, Kurola J, Tiainen M, Pettilä V, Bendel S, Varpula T, Latini R, Ristagno G, Skrifvars MB. Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. Resuscitation. 2022. In press. (I.F. 4.572)

208. Selmaj K, Mycko M, Furlan R, Rejdak K. Fluid phase biomarkers in MS. Curr. Op. Neurol. 2022. 35:286-292. doi: 10.1097/WCO.0000000000001058. (I.F. 4.88)

209. Ponzano M, Schiavetti I, Bovis F, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Bragadin MM, Cocco E, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Bergamaschi R, Inglese M, Petracca M, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Karabudak R, Efendi H, Furlan R, Salvetti M, Sormani MP. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Mult Scler Relat Disord. 2022 Jul;63:103909. doi: 10.1016/j.msard.2022.103909. Epub 2022 May 25. PMID: 35675744 (I.F. 5.412)

210. Falzone YM, Domi T, Mandelli A, Pozzi L, Schito P, Russo T, Barbieri A, Del Carro U, Malaspina A, Agosta F, Quattrini A, Furlan R, Filippi M, Riva N. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2022. 29:1930-1939. doi: 10.1111/ene.15321. (I.F. 6.089).

211. Azzolini F, Gilio L, Pavone L, Iezzi E, Dolcetti E, Bruno A, Buttari F, Musella A, Mandolesi G, Guadalupi L, Furlan R, Finardi A, Micillo T, Carbone F, Matarese G, Centonze D, Stampanoni Bassi M. Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Biomolecules. 2022 12:222. doi: 10.3390/biom12020222. (I.F. 4.569)

212. Guerrera G*, Mandelli A*, Finardi A, Orrico M, D'Orso S, Picozza M, Noviello M, Beretta V, Bonetti B, Calabrese M, Marastoni D, De Rossi N, Capra R, Salvetti M, Buscarinu MC, Inglese M, Uccelli A, Moiola L, Raposo C, Muros-Le Rouzic E, Pedotti R, Filippi F, Bonini C, Battistini L, Borsellino G*, Furlan R2* on behalf of the Italian Covid-19 Alliance in MS. Anti-SARS-CoV-2 T stem cell memory persists in ocrelizumab treated MS patients. Mult. Scler. 2022 28:1937-1943. doi: 10.1177/13524585221102158. (I.F. 6.312)

213. Manenti S, Orrico M, Masciocchi S, Mandelli A, Finardi A, Furlan R. PD-1/PD-L Axis in Neuroinflammation: New Insights. Front Neurol. 2022 13:877936. doi: 10.3389/fneur.2022.877936. eCollection 2022. (I.F. 3.552)

214. Bruno A, Dolcetti E, Azzolini F, Moscatelli A, Gambardella S, Ferese R, Rizzo FR, Gilio L, Iezzi E, Galifi G, Borrelli A, Buttari F, Furlan R, Finardi A, De Vito F, Musella A, Guadalupi

L, Mandolesi G, Centonze D, Stampanoni Bassi M. Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis. Genes 2022. 13(5):897. doi: 10.3390/genes13050897. (I.F. 3.688)

215. Poletti S, Paolini M, Mazza MG, Palladini M, Furlan R, Querini PR; Covid BioB Outpatients Clinic Study Group, Benedetti F. Lower levels of glutathione in the anterior cingulate cortex associate with depressive symptoms and white matter hyperintensities in COVID-19 survivors. Eur Neuropsychopharmacol. 2022 61:71-77. doi: 10.1016/j.euroneuro.2022.06.008. Epub 2022 Jun 29.PMID: 35810586 (I.F. 5.414)

216. Gilio L, Fresegna D, Gentile A, Guadalupi L, Sanna K, De Vito F, Balletta S, Caioli S, Rizzo FR, Musella A, Iezzi E, Moscatelli A, Galifi G, Fantozzi R, Bellantonio P, Furlan R, Finardi A, Vanni V, Dolcetti E, Bruno A, Buttari F, Mandolesi G, Centonze D, Stampanoni Bassi M. Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis. Neurobiol Dis. 2022 172:105817. doi: 10.1016/j.nbd.2022.105817. Online ahead of print. PMID: 35835361 (I.F. 5.996).

217. Ballerini C, Njamnshi AK, Juliano SL, Kalaria RN, Furlan R, Akinyemi RO. Non-Communicable Neurological Disorders and Neuroinflammation. Front Immunol. 2022 13:834424. doi: 10.3389/fimmu.2022.834424. eCollection 2022. PMID: 35769472 (I.F. 6.429)

218. Enrico P, Delvecchio G, Turtulici N, Aronica R, Pigoni A, Squarcina L, Villa F, Perlini C, Rossetti MG, Bellani M, Lasalvia A, Bonetto C, Scocco P, D'Agostino A, Torresani S, Imbesi M, Bellini F, Veronese A, Bocchio-Chiavetto L, Gennarelli M, Balestrieri M, Colombo G, Finardi A, Ruggeri M, Furlan R, Brambilla P. A machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup. Mol. Psychiatry. 2023 Jan 6. doi: 10.1038/s41380-022-01911-1. (I.F. 15.992).

219. Genchi A, Brambilla E, Sangalli F, Radaelli M, Bacigaluppi M, Furlan R, Andolfo A, Drago D, Magagnotti C, Scotti G, Greco R, Vezzulli P, Ottoboni L, Bonopane M, Capilupo D, Ruffini F, Belotti D, Cabiati B, Cesana S, Matera G, Leocani L, Martinelli V, Moiola L, Vago L, Panina-Bordignon P, Falini A, Ciceri F, Uglietti A, Sormani MP, Comi G, Battaglia MA, Rocca M, Storelli L, Pagani E, Gaipa G, Martino G. Neural stem cell transplantation in patients with progressive multiple sclerosis: An open label, phase I study. Nat Med. 2023 Jan 9. doi: 10.1038/s41591-022-02097-3 (I.F. 35.09)

220. Masocha W, Idro R, Furlan R, Lakhdar-Ghazal N. Editorial: Neuroimmunology in Africa. Front Immunol. 2023 May 2;14:1201494. doi: 10.3389/fimmu.2023.1201494. eCollection 2023. PMID: 37207225 (I.F. 8.787).

221. Bruno A, Dolcetti E, Azzolini F, Buttari F, Gilio L, Iezzi E, Galifi G, Borrelli A, Furlan R, Finardi A, Carbone F, De Vito F, Musella A, Guadalupi L, Mandolesi G, Matarese G, Centonze D, Stampanoni Bas si M.BACE1 influences clinical manifestations and central inflammation in relapsing remitting multiple sclerosis. Mult Scler Relat Disord. 2023 Mar;71:104528. doi: 10.1016/j.msard.2023.104528. Epub 2023 Jan 24. PMID: 3670957 (I.F. 4.808)

222. Gilio L, Buttari F, Pavone L, Iezzi E, Galifi G, Dolcetti E, Azzolini F, Bruno A, Borrelli A, Storto M, Furlan R, Finardi A, Pekmezovic T, Drulovic J, Mandolesi G, Fresegna D, Vanni V, Centonze D, Stampanoni Bassi M. Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity. Biomedicines. 2022 Aug 23;10(9):2058. doi: 10.3390/biomedicines10092058. PMID: 36140159 (I.F. 4.757)

223. Abdelhak A, Barba L, Romoli M, Benkert P, Conversi F, D'Anna L, Masvekar RR, Bielekova B, Prudencio M, Petrucelli L, Meschia JF, Erben Y, Furlan R, De Lorenzo R, Mandelli A,

Sutter R, Hert L, Epple V, Marastoni D, Sellner J, Steinacker P, Aamodt AH, Heggelund L, Dyrhol-Riise AM, Virhammar J, Fällmar D, Rostami E, Kumlien E, Blennow K, Zetterberg H, Tumani H, Sacco S, Green AJ, Otto M, Kuhle J, Ornello R, Foschi M, Abu-Rumeileh S. Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis.J Neurol. 2023 270(7):3315-3328. doi: 10.1007/s00415-023-11768-1. Epub 2023 May 15. PMID: 37184659 (I.F.6.682)

224. Colombo E, De Angelis A, Bassani C, Ruffini F, Ottoboni L, Garzetti L, Finardi A, Martino G, Furlan R, Farina C. iAstrocytes do not restrain T cell proliferation in vitro. BMC Neurosci. 2023 24(1):33. doi: 10.1186/s12868-023-00806-3. PMID: 37286983 (I.F. 3.264).

225. Errico F, Gilio L, Mancini A, Nuzzo T, Bassi MS, Bellingacci L, Buttari F, Dolcetti E, Bruno A, Galifi G, Furlan R, Finardi A, Di Maio A, Di Filippo M, Centonze D, Usiello A. Cerebrospinal fluid, brain, and spinal cord levels of L-aspartate signal excitatory neurotransmission abnormalities in multiple sclerosis patients and experimental autoimmune encephalomyelitis mouse model. J Neurochem. 2023 166(3):534-546. doi: 10.1111/jnc.15884. PMID: 37332201 (I.F.5.546).

226. Magliocca A, Perego C, Motta F, Merigo G, Micotti E, Olivari D, Fumagalli F, Lucchetti J, Gobbi M, Mandelli A, Furlan R, Skrifvars MB, Latini R, Bellani G, Ichinose F, Ristagno G. Indoleamine 2,3-Dioxygenase Deletion to Modulate Kynurenine Pathway and to Prevent Brain Injury After Cardiac Arrest in Mice. Anesthesiology. 2023 Jul 24. doi: 10.1097/ALN.0000000000004713. (I.F. 9.198)

227. Dolcetti E, Bruno A, Azzolini F, Gilio L, Pavone L, Iezzi E, Galifi G, Gambardella S, Ferese R, Buttari F, De Vito F, Colantuono P, Furlan R, Finardi A, Musella A, Mandolesi G, Centonze D, Stampanoni Bassi M. Genetic regulation of IL-8 influences disease presentation of multiple sclerosis. Mult Scler. 2023 29(4-5):512-520. doi: 10.1177/13524585231155049. Epub 2023 Feb 19. PMID: 36803228 (I.F. 5.855)

228. De Vito F, Balletta S, Caioli S, Musella A, Guadalupi L, Vanni V, Fresegna D, Bassi MS, Gilio L, Sanna K, Gentile A, Bruno A, Dolcetti E, Buttari F, Pavone L, Furlan R, Finardi A, Perlas E, Hornstein E, Centonze D, Mandolesi G. MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis. Curr Neuropharmacol. 2023;21(12):2567-2582. doi: 10.2174/1570159X21666230404103914. PMID: 37021418 (I.F. 7.708)

229. Schito P, Russo T, Domi T, Mandelli A, Pozzi L, Del Carro U, Carrera P, Agosta F, Quattrini A, Furlan R, Filippi M, Riva N. Clinical and neurochemical biomarkers differentiate Primary Lateral Sclerosis from upper motor neuron Amyotrophic Lateral Sclerosis. J Neurol. 2023 101:352-356. doi: 10.1212/WNL.0000000000207223. (I.F. 11.360)

230. Bruno A, Buttari F, Dolcetti E, Azzolini F, Borrelli A, Lauritano G, Di Caprio V, Rizzo FR, Gilio L, Galifi G, Furlan R, Finardi A, Guadalupi L, Musella A, Mandolesi G, Centonze D, Stampanoni Bassi M. Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis. Mult Scler. 2023 Oct;29(11-12):1383-1392. doi: 10.1177/13524585231197928. (I.F. 5.855)

231. Wilson D, Chan D, Chang L, Mathis R, Verberk I, Montalban X, Comabella M, Fissolo N, Bielekova B, Masvekar R, Chitnis T, Ziemssen T, Akgün K, Blennow K, Zetterberg H, Brück W, Giovannoni G, Gnanapavan S, Bittner S, Zipp F, Comi G, Furlan R, Lehmann S, Thebault S, Freedman M, Bar-Or A, Kramer M, Otto M, Halbgebauer S, Hrusovsky K, Plavina T, Khalil M, Piehl F, Wiendl H, Kappos L, Maceski A, Willemse E, Leppert D, Teunissen C, Kuhle J. Development and Multi-Center Validation of a Fully Automated Digital Immunoassay for Neurofilament Light Chain: Toward a Clinical Blood Test for

Neuronal Injury. Clinical Chemistry and Laboratory Medicine. doi: 10.1515/cclm-2023-0518. (I.F. 6.8)

232. Leppert D, Watanabe M, Schaedelin S, Piehl F, Furlan R, Gastaldi M, Lambert J, Evertsson B, Fink K, Matsushita T, Masaki K, Isobe N, Kira JI, Benkert P, Maceski A, Willemse E, Oechtering J, Orleth A, Meier S, Kuhle J. Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 94(9):726-737. doi: 10.1136/jnnp-2022-330796. Epub 2023 Apr 19. PMID: 37076291 (I.F. 13.654)

233. Montini F, Nozzolillo A, Tedone N, Mistri D, Rancoita PM, Zanetta C, Mandelli A, Furlan R, Moiola L, Martinelli V, Rocca MA, Filippi M; Clinical SanRaf MS Study Group. COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study. J Neurol Neurosurg Psychiatry. 2023 doi: 10.1136/jnnp-2023-332073. Online ahead of print. (I.F. 13.654)

234. Fissolo N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, Vilaseca-Jolonch A, Llufriu S, Blanco Y, Hegen H, Berek K, Perez-Miralles F, Rejdak K, Villar LM, Monreal E, Alvarez-Lafuente R, Soylu OK, Abdelhak A, Bachhuber F, Tumani H, Martínez-Yélamos S, Sánchez-López AJ, García-Merino A, Gutiérrez L, Castillo-Trivino T, Lycke J, Rosenstein I, Furlan R, Filippi M, Téllez N, Ramió-Torrentà L, Lünemann JD, Wiendl H, Eichau S, Khalil M, Kuhle J, Montalban X, Comabella M. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 jnnp-2023-332251. doi: 10.1136/jnnp-2023-332251. (I.F. 11.1)

235. Aggio V, Fabbella L, Poletti S, Lorenzi C, Finardi A, Colombo C, Zanardi R, Furlan R, Benedetti F. Circulating cytotoxic immune cell composition, activation status and toxins expression associate with white matter microstructure in bipolar disorder. Sci Rep. 2023 13(1):22209. doi: 10.1038/s41598-023-49146-6. (I.F. 4.6)

236. Ulutekin C, Galli E, Schreiner B, Khademi M, Callegari I, Piehl F, Sanderson N, Kirschenbaum D, Mundt S, Filippi M, Furlan R, Olsson T, Derfuss T, Ingelfinger F, Becher B. B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis. Cell Rep Med. 2024 5(1):101351. doi: 10.1016/j.xcrm.2023.101351. (I.F. 16.988)

237. Turano E, Scambi I, Bonafede R, Dusi S, Angelini G, Lopez N, Marostica G, Rossi B, Furlan R, Constantin G, Mariotti R, Bonetti B. Extracellular vesicles from adipose mesenchymal stem cells target inflamed lymph nodes in experimental autoimmune encephalomyelitis. Cytotherapy. 2024 S1465-3249(24)00001-X. doi: 10.1016/j.jcyt.2023.12.007 (I.F. 5.414)

238. Poletti S, Zanardi R, Mandelli A, Aggio V, Finardi A, Lorenzi C, Borsellino G, Carminati M, Manfredi E, Tomasi E, Spadini S, Colombo C, Drexhage HA, Furlan R, Benedetti F. Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers. Brain Behav Immun. 2024 S0889-1591(24)00255-1. doi: 10.1016/j.bbi.2024.02.019. (I.F. 15.1)

239. Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Di Caprio V, Lauritano G, Borrelli A, Galifi G, Furlan R, Finardi A, Musella A, Guadalupi L, Mandolesi G, Rovella V, Centonze D, Stampanoni Bassi M. Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients. 2024 Front. Neurol. In press. (I.F. 3.4)

240. Perego C, Fumagalli F, Motta F, Cerrato M, Micotti E, Olivari D, De Giorgio D, Merigo G, Di Clemente A, Mandelli A, Forloni G, Cervo L, Furlan R, Latini R, Neumar RW, Ristagno G. Evolution of brain injury and neurological dysfunction after cardiac arrest in the rat - A multimodal and comprehensive model. J Cereb Blood Flow Metab. 2024 21:271678X241255599. doi: 10.1177/0271678X241255599. (I.F. 6.3)

241. Fusco C, De Rosa G, Spatocco I, Vitiello E, Procaccini C, Frigè C, Pellegrini V, La Grotta R, Furlan R, Matarese G, Prattichizzo F, de Candia P.Extracellular vesicles as human therapeutics: A scoping review of the literature. J Extracell Vesicles. 2024 13(5):e12433. doi: 10.1002/jev2.12433. (I.F. 16.0)

242. Dolcetti E, Musella A, Balletta S, Gilio L, Bruno A, Stampanoni Bassi M, Lauritano G, Buttari F, Fresegna D, Tartacca A, Mariani F, Palmerio F, Rovella V, Ferese R, Gambardella S, Giardina E, Finardi A, Furlan R, Mandolesi G, Centonze D, De Vito F. Interaction between miR-142-3p and BDNF Val/Met Polymorphism Regulates Multiple Sclerosis Severity. Int J Mol Sci. 2024 11;25(10):5253. doi: 10.3390/ijms25105253. (I.F. 5.6)

243. Dalla Costa G, Leocani L, Pisa M, Croese T, Martinelli V, Moiola L, Sangalli F, Colombo B, Haghikia A, Gold R, Furlan R, Comi G. Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres. Mult Scler. 2024 Jun 14:13524585241260977. doi: 10.1177/13524585241260977. (IF 4.8)

244. De Lorenzo R, Loré NI, Finardi A, Mandelli A, Calesella F, Palladini M, Cirillo DM, Tresoldi C, Ciceri F, Rovere-Querini P, Manfredi AA, Mazza MG, Benedetti F, Furlan R. Inflammatory Markers Predict Blood Neurofilament Light Chain Levels in Acute COVID-19 Patients. Int J Mol Sci. 2024 Jul 29;25(15):8259. doi: 10.3390/ijms25158259. (IF 5.6)

245. Gilio L, Fresegna D, Stampanoni Bassi M, Musella A, De Vito F, Balletta S, Sanna K, Caioli S, Pavone L, Galifi G, Simonelli I, Guadalupi L, Vanni V, Buttari F, Dolcetti E, Bruno A, Azzolini F, Borrelli A, Fantozzi R, Finardi A, Furlan R, Centonze D, Mandolesi G. Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis. Front Mol Neurosci. 2024 Aug 7;17:1430080. doi: 10.3389/fnmol.2024.1430080. (IF 5.7)

246. Femiano C, Bruno A, Gilio L, Buttari F, Dolcetti E, Galifi G, Azzolini F, Borrelli A, Furlan R, Finardi A, Musella A, Mandolesi G, Storto M, Centonze D, Stampanoni Bassi M. Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression. Sci Rep. 2024 Aug 27;14(1):19796. doi: 10.1038/s41598-024-67165-9. (IF 3.8)

247. Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Borrelli A, Di Caprio V, Lauritano G, Galifi G, Gambardella S, Ferese R, Giardina E, Rovella V, Furlan R, Finardi A, Musella A, Balletta S, Mandolesi G, Centonze D, Stampanoni Bassi M. An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis. Int J Mol Sci. 2024 Aug 22;25(16):9108. doi: 10.3390/ijms25169108. (IF 5.6)

248. Stampanoni Bassi M, Gilio L, Galifi G, Buttari F, Dolcetti E, Bruno A, Belli L, Modugno N, Furlan R, Finardi A, Mandolesi G, Musella A, Centonze D, Olivola E. disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammation. Parkinsonism Relat Disord. 2024 May;122:106071. doi: 10.1016/j.parkreldis.2024.106071. (I.F. 4.1)

249. De Lorenzo R, Loré NI, Finardi A, Mandelli A, Calesella F, Palladini M, Cirillo DM, Tresoldi C, Ciceri F, Rovere-Querini P, Manfredi AA, Mazza MG, Benedetti F, Furlan R. Inflammatory Markers Predict Blood Neurofilament Light Chain Levels in Acute COVID-19 Patients. Int J Mol Sci. 2024 25(15):8259. doi: 10.3390/ijms25158259. (I.F. 4.1)

250. Della Vecchia S, Gammaldi N, Ricca I, Mero S, Doccini S, Ardissone A, Bagnoli S, Battini R, Colombi E, Favaro J, Furlan R, Giordano L, Ingannato A, Mandelli A, Manzoni FMP, Milito G, Moroni I, Nacmias B, Nardocci N, Parmeggiani L, Pezzini F, Pietrafusa N, Sartori S, Specchio N, Trivisano M, Ets ACL, Simonati A, Santorelli FM; A-NCL ETS Group. Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses. J Neurol. 2025 Jan 7;272(1):94. doi: 10.1007/s00415-024-12790-7. (I.F. 4.8)

251. Centonze D, Di Sapio A, Brescia Morra V, Colombo E, Inglese M, Paolicelli D, Salvetti M, Furlan R. Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice. Front Neurol 2025. 16:1571605. doi: 10.3389/fneur.2025.1571605. (I.F. 2.7)

252. Moiola L, Mandelli A, Tarkowski M, Finardi A, Gabrieli A, Zanetta C, Viti V, Gattuso I, Esposito F, Pedotti R, Muros-Le Rouzic E, Raposo C, Rocca M.A., Locatelli M, Bonini C, Furlan R, Riva A, Filippi M. Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab. J Neurol 2025. 272:314. doi: 10.1007/s00415-025-13027-x. (I.F. 4.8).

253. Antonini Cencicchio M, Montini F, Palmieri V, Massimino L, Lo Conte M, Finardi A, Mandelli A, Asnicar F, Pavlovic R, Drago D, Ungaro F, Andolfo A, Segata N, Martinelli V, Furlan R, Falcone M. Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity. Cell Rep Med. 2025 Apr 15;6(4):102028. doi: 10.1016/j.xcrm.2025.102028. (I.F. 11.7)

254. Peralta Ramos JM, Castellani G, Kviatcovsky D, Croese T, TsitsouKampeli A, Burgaletto C, Abellanas MA, Cahalon L, Colaiuta SP, Salame TM, Kuperman T, Savidor A, Itkin M, Malitsky S, Ovadia S, Ferrera S, Kalfon L, Kadmani S, Samra N, Paz R, Rokach L, Furlan R, AharonPeretz J, Falik-Zaccai TC, Schwartz M. Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition 2 in a mouse model of Alzheimer's disease. Nat Comm. 2025 In press. (I.F. 14.7).

255. Fissolo N, Schaedelin S, Villar LM, Lünemann JD, Correale J, Rejdak K, Schwab N, Vilaseca A, Held F, García-Merino A, Bittner S, Trojano M, Furlan R, Tumani H, Pérez-Miralles F, Rosenstein I, Galimberti D, Álvarez-Bravo G, Thouvenot E, Llufriu S, Khoury SJ, Hoepner R, Martínez-Yélamos S, Hegen H, Drulovic J, Téllez-Lara N, Khalil M, Oechtering J, Pérez-Sempere Á, Rodríguez-Antigüedad A, Enrique-Martínez J, Strijbis E, Killestein J, Eichau S, Colombo E, Schaller-Nagengast J, Midaglia L, Sánchez-López AJ, Monreal E, Chan A, Paul F, Rovira À, Tintoré M, Lycke J, Zipp F, Hemmer B, Kuhle J, Montalban X, Comabella M; RIS Study Group; Zettl UK, Falk S, Gutiérrez L, Gasior M, Veiga González JL, Ferrer R, Quiroga-Varela A, Bachhuber F, Costa-Frossard L. Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome. JAMA Neurol. 2025 Jun 2:e251481. doi: 10.1001/jamaneurol.2025.1481. (I.F.20.4)

256. De Rosa G, Russo C, Garavelli S, Di Silvestre D, Spatocco I, Mele G, La Rocca C, Colamatteo A, Carbone F, Fusco C, Passaro F, Carpi D, Tagliabue E, Prattichizzo F, Brambilla F, Mauri P, Hoxha M, Bollati V, Giusti I, Dolo V, D'Antona P, Campomenosi P, Mangolini V, Radeghieri A, Bergese P, Morabito I, Mandelli A, Finardi A, Beretta F, Schilke ED, Cavaletti G, Dolcetti E, Buttari F, Abbadessa G, Bonavita S, Lus G, Signoriello E, Lanzillo R, Morra VB, Mottola M, Zuccarelli B, Uccelli A, Salvetti M, Centonze D, Furlan R, Matarese G, Procaccini C, de Candia P. MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis. Sci Transl Med. 2025 May 28;17(800):eadl1698. doi: 10.1126/scitranslmed.adl1698. (I.F. 17.1)

257. Pisa M, Croese T, Costa GD, Congiu M, Gelibter S, Orrico M, Moiola L, Comi G, Furlan R, Leocani L. Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis. Neurol Sci. 2025 May 21. doi: 10.1007/s10072-025-08198-4. (I.F.3.2)

258. Palladini M, Mazza MG, Bravi B, Bessi M, Lorenzi MC, Spadini S, De Lorenzo R, Rovere-Querini P, Furlan R, Benedetti F. Sex-Specific Inflammatory Profiles Affect Neuropsychiatric Issues in COVID-19 Survivors. Biomolecules. 2025 Apr 18;15(4):600. doi: 10.3390/biom15040600. (I.F. 4.8).

259. Rossi B, Virla F, Angelini G, Scambi I, Bani A, Marostica G, Caprioli M, Anni D, Furlan R, Marzola P, Mariotti R, Constantin G, Bonetti B, Turano E. Intranasal Administration of Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Has Therapeutic Effect in Experimental Autoimmune Encephalomyelitis. Cells. 2025 14(15):1172. doi: 10.3390/cells14151172. (I.F. 5.2)

260. Margoni M, Battistini L, Centonze D, Furlan R, Gasperini C, Filippi M. Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment. Curr Neuropharmacol. 2025 Aug 26. doi: 10.2174/011570159X392955250815095236. (I.F. 2.2)

Data 23 Settembre 2025 Firma 

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Data 23 Settembre 2025 Firma 

Il sottoscritto Roberto Furlan nato a Frankfurt-M in data 5 aprile 1964, residente a Novate Milanese (Mi) in Via Campo dei Fiori 32, con codice fiscale FRLRRT64D05Z112S

DICHIARA

Ai sensi degli articoli 46 e 47 del DPR 28/12/2000, n. 445, consapevole delle sanzioni penali previste dall'art. 76 del suddetto DPR per le ipotesi di falsità in atti e dichiarazioni mendaci indicate, che quanto indicato nel CV corrisponde a verità.

Data 23 Settembre 2025 Firma